Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Feb;128(3):439-440.
doi: 10.1038/s41416-023-02146-9. Epub 2023 Feb 16.

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhönen, T Kuitunen, P Nyandoto & M Kouri

Naureen Starling  1 , David Cunningham  2
Affiliations
Randomized Controlled Trial

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S Pyrhönen, T Kuitunen, P Nyandoto & M Kouri

Naureen Starling et al. Br J Cancer. 2023 Feb.

Abstract

We discuss Pyrhönen's paper as a catalyst for defining systemic therapy approaches in gastric cancer and how the field has evolved in the last two decades in sequential, targeted and more recently immune-directed therapies and how it may develop to transform survival in this cancer of high unmet need.

PubMed Disclaimer

Conflict of interest statement

Within the last 5 years, COI for both authors is detailed: NS and DC are supported by the NIHR Biomedical Research Centre at The Royal Marsden and Institute for Cancer Research. NS is supported by the following grants: NIHR NIHR128529 and SBRI SBRIC01P3008. DC is supported by NIHR128529. NS: Honoraria: Merck Serono, Novartis, MSD Oncology, Eli Lilly, Pierre Fabre, Amgen, GSK, Servier, Pierre Fabre. Advisory role; Pfizer, Servier, AstraZeneca, MSD Oncology Novartis, Bayer, GSK, Guardant Health, Gilead, Seagen; Research support: Pfizer, AstraZeneca, Guardant Health Travel/accommodation support: Roche, BMS, MSD DC: Research funding: MedImmune/AZ, Clovis, Eli Lilly, 4SC, Bayer, Celgene, Leap, Advisory: OVIBIO.

Similar articles

See all similar articles

References

    1. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–91. doi: 10.1038/bjc.1995.114. - DOI - PMC - PubMed
    1. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20:1996–2004. doi: 10.1200/JCO.2002.08.105. - DOI - PubMed
    1. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46. doi: 10.1056/NEJMoa073149. - DOI - PubMed
    1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. doi: 10.1056/NEJMoa055531. - DOI - PubMed
    1. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57. doi: 10.1016/S0140-6736(18)32557-1. - DOI - PubMed

Publication types

MeSH terms